Definition

PMOS — Polyendocrine Metabolic Ovarian Syndrome — is the new name for the condition previously called PCOS, or polycystic ovary syndrome. The change was agreed through a global consensus process published in The Lancet in 2026 and reflects what the condition actually is: a multisystem endocrine and metabolic disorder, not a disease of ovarian cysts. It affects roughly one in eight women.

Why It Matters

The old name was actively misleading. The "cysts" seen on ultrasound in PCOS are not pathological cysts at all — they are immature follicles that have stalled partway through development. By naming the condition after them, the old term pushed attention toward the ovaries and away from the insulin resistance, androgen excess and cardiometabolic risk that drive it. The consensus paper notes that this contributed to delayed diagnosis, fragmented care and stigma. The new name puts the endocrine and metabolic features where they belong: in the name itself.

Related Conditions

Pcos Insulin Resistance Infertility Support Amenorrhea

Related Modalities

Functional Lab Testing Clinical Nutrition Lifestyle Medicine Nutraceuticals

Frequently Asked Questions

Yes — they are the same condition. PMOS (Polyendocrine Metabolic Ovarian Syndrome) is simply the new, more accurate name for what has been called PCOS (polycystic ovary syndrome). Nothing about your diagnosis, your body or your treatment changes because the name changed. If you were diagnosed with PCOS, you have PMOS; they are one and the same.

No. Most clinicians, medical records, insurance systems and billing codes still use PCOS, and will for some time — the ICD diagnostic codes have not changed yet. The consensus paper describes a deliberate transition period rather than an overnight switch. Use whichever term your care team uses; they refer to the same condition.

Because the old one was inaccurate. The "cysts" are not cysts — they are follicles that stopped developing. Naming the condition after an ovarian appearance obscured the fact that it is fundamentally an endocrine and metabolic disorder involving insulin resistance and androgen excess. The 2026 Lancet consensus involved 56 organisations and over 14,000 people with the condition, and concluded that scientific accuracy mattered more than keeping a familiar acronym.